China-based Harbour BioMed (HKG: 2142) announced the appointment of Michael D. Patten as Chief Strategy Officer. Based in the United States, Michael will report directly to Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed. This strategic move aims to enhance Harbour BioMed’s global influence and business expansion.
Role and Responsibilities
In his role, Michael will be responsible for formulating and overseeing the global corporate development and growth strategy for Harbour BioMed. As Head of Global Alliance, he will also lead efforts to manage and strengthen the company’s global strategic partner network and ecosystem, with a focus on high-potential markets outside of China.
Michael’s Background and Experience
Michael brings extensive experience and a strong track record in the biopharmaceutical industry. During his tenure at Bristol Myers Squibb, he held several key leadership roles. Most recently, as Head of Equity & Venture Capital, he led and managed significant numbers of strategic equity investments and LP commitments across the life science ecosystem. Previously, he held roles of increasing seniority in Business Development and Alliance Leadership, successfully executing transactions and managing multiple early- and late-stage business development alliances.-Fineline Info & Tech
Leave a Reply